Article
Clinical Neurology
George M. Anderson, Christine M. Ramsey, Kevin G. Lynch, Joel Gelernter, David W. Oslin
Summary: This study investigated the distribution of baseline platelet serotonin (5-HT) levels in depression patients seeking treatment and defined subgroups based on drug exposure. The bioeffect of 5-HT reuptake inhibitors (SRIs) and the relationship between demographic variables and platelet 5-HT concentration were also assessed. Data from a cross-sectional study of 1433 Veterans Administration (VA) patients were analyzed, revealing a bimodal distribution of platelet 5-HT levels and significant differences in population, sex, and age.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Medicine, General & Internal
Daniel Richter, Jeyanthan Charles James, Andreas Ebert, Aristeidis H. Katsanos, Lisa Mazul-Wach, Quirin Ruland, Ralf Gold, Georg Juckel, Christos Krogias
Summary: Early SSRI therapy is associated with a reduced risk of post-stroke depression, but increases the risk of bone fracture and nausea. Future research should focus on identifying high-risk individuals to improve the risk-benefit assessment of this therapy in clinical practice.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Psychology, Clinical
Chittaranjan Andrade
Summary: The exposure to antidepressants during pregnancy, especially SSRIs, is associated with a slightly increased risk of postpartum hemorrhage. However, the findings should be interpreted with caution, and precautionary measures are still recommended.
JOURNAL OF CLINICAL PSYCHIATRY
(2022)
Article
Oncology
Min-Jing Lee, Chien-Wei Huang, Yi-Lung Chen, Yao-Hsu Yang, Vincent Chin-Hung Chen
Summary: The study revealed an association between the use of SSRIs and decreased risk of kidney cancer, with citalopram and paroxetine showing protective effects in depressed patients with kidney cancer during a 2-year induction period.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Pharmacology & Pharmacy
Jill S. S. Chotiyanonta, Kengo Onda, Milap A. A. Nowrangi, Xin Li, Xin Xu, Roy Adams, Constantine G. G. Lyketsos, Peter Zandi, Kenichi Oishi
Summary: This study aimed to investigate the responder rates of cholinesterase inhibitors and selective serotonin reuptake inhibitors in an outpatient setting using electronic medical records. The results showed that the medication effects were similar to previous clinical trials in various types of dementia patients.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Clinical Neurology
Martin J. Lan, Francesca Zanderigo, Spiro P. Pantazatos, M. Elizabeth Sublette, Jeffrey Miller, R. Todd Ogden, J. John Mann
Summary: Disturbance of serotonin system function is associated with both the diagnosis of BD and its severity of depression. Pretreatment 5HT1AR binding did not predict SSRI antidepressant outcome.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Soobeen Hwang, Jong-Hui Kim, Su-Hyun Jo
Summary: Paroxetine can acutely and directly modulate human Kv1.3 channels, inhibiting channel activity by accelerating steady-state inactivation, thus revealing a possible mechanism for acute immunosuppression.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Environmental Sciences
Rafael R. Domingues, Hannah P. Fricke, Celeste M. Sheftel, Autumn M. Bell, Luma C. Sartori, Robbie S. J. Manuel, Chandler J. Krajco, Milo C. Wiltbank, Laura L. Hernandez
Summary: The effects of SSRI drugs on pregnancy and neonatal outcomes in mice were investigated. The study found that the high dose of fluoxetine led to a decrease in pregnancy rate and maternal weight gain, while both high and low doses of sertraline led to a decrease in the number of pups born and weaned. The study suggests that the effects of SSRI on neonatal mortality may be mediated by SSRI-induced placental insufficiency.
Review
Neurosciences
George M. Anderson, Isabella Bruno-Pacella
Summary: This article assesses the bioeffect of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and compares them using neuroimaging and in vitro measurements. The study finds that these drugs typically result in a 70-90% reduction in platelet serotonin (5-HT) content. The bioeffect is similar among different types of SSRIs and SNRIs and is consistent with other assessment methods.
PSYCHOPHARMACOLOGY
(2023)
Review
Neurosciences
Robyn P. Thom, Michelle L. Palumbo, Claire Thompson, Christopher J. McDougle, Caitlin T. Ravichandran
Summary: The study found that the majority of adults with Down syndrome responded positively to a 12-week course of SSRI treatment for depression, with some experiencing adverse effects such as daytime sedation and anger. Controlled studies are needed to further evaluate the efficacy, tolerability, and safety of SSRIs in this population.
Review
Anesthesiology
Li Wang, Joshua Tobe, Emily Au, Cody Tran, Jane Jomy, Yvgeniy Oparin, Rachel J. Couban, James Paul
Summary: The systematic review and meta-analysis found that SSRIs and SNRIs as adjuncts for postoperative pain management significantly reduced postoperative pain, opioid consumption, and improved patient satisfaction without increasing adverse events compared with placebo. SSRIs tend to be less effective than SNRIs, but the effects of SSRIs remain inconclusive due to limited evidence.
BRITISH JOURNAL OF ANAESTHESIA
(2022)
Review
Pharmacology & Pharmacy
Thanh Thanh L. Nguyen, Duan Liu, Ming-Fen Ho, Arjun P. Athreya, Richard Weinshilboum
Summary: The application of a multi-omics research strategy that used metabolomics to inform genomics, followed by functional genomic studies, identified novel genes that influenced monoamine biology and allowed the development of a predictive algorithm for SSRI clinical outcomes in MDD. This approach could be broadly applicable for the study of other neuropsychiatric diseases and their drug therapy.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Juhee Lim, Yeojin Bang, Kyeong-Man Kim, Hyun Jin Choi
Summary: This study investigated the effects of differentiation on the serotonergic neuronal phenotype of the mouse hippocampal neuronal cell line HT22. The results showed that differentiation promoted neurite outgrowth and upregulation of N-methyl-D-aspartate receptor and choline acetyltransferase in HT22 cells. Furthermore, proteins required for serotonergic neurotransmission were significantly upregulated in differentiated HT22 cells. These findings suggest that differentiated HT22 cells have enhanced functional serotonergic properties and could be used for assessing the efficacy of antidepressant 5-HT reuptake inhibitors.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Clinical Neurology
Patryk Kubiszewski, Lansing Sugita, Christina Kourkoulis, Zora DiPucchio, Kristin Schwab, Christopher D. Anderson, M. Edip Gurol, Steven M. Greenberg, Anand Viswanathan, Jonathan Rosand, Alessandro Biffi
Summary: This study found that the use of selective serotonin reuptake inhibitors (SSRIs) among survivors of intracerebral hemorrhage (ICH) may increase the risk of ICH recurrence, but also alleviate depressive symptoms. The research suggests that clinicians can assess the suitability of SSRI use in ICH survivors by considering clinical history, neuroimaging data, and genetic biomarkers.
Article
Psychiatry
Lijun Liu, Xiaozhen Lv, Shuzhe Zhou, Qi Liu, Jing Wang, Hongjun Tian, Kerang Zhang, Jing Wei, Chuanyue Wang, Qiaoling Chen, Gang Zhu, Xueyi Wang, Nan Zhang, Yu Huang, Tianmei Si, Xin Yu
Summary: The study aimed to explore the impact of SSRIs on cognitive function in depressed patients and identify factors associated with cognitive remission and nonremission. Results showed that most patients experienced improvements in cognitive function after treatment, but only a minority achieved cognitive remission.
JOURNAL OF PSYCHIATRIC RESEARCH
(2021)